News & Updates

Obesity does not appear to elevate the risk of death in critically ill patients with COVID-19, results of a study have shown. In addition, patients with BMI <25 kg/m2 have a higher rate of mortality than those with greater BMI levels.

Individuals with type 2 diabetes (T2D) treated in routine clinical care appear to fare better with glucagon-like peptide-1 receptor agonists (GLP-1RAs) than with dipeptidyl peptidase-4 inhibitors (DPP-4is), with GLP-1Ras being associated with lower rates of hyperkalemia and renin-angiotensin system inhibitor (RASi) medication discontinuation, as shown in an observational study.

The incidence of cirrhosis and hepatocellular carcinoma (HCC) among veterans differs according to demographic and clinical characteristics, with the lowest rate seen among Asians, reports a study.

Combination therapy with sodium-glucose transporter inhibitors (SGLT2i) and glucagon-like peptide receptor agonists (GLP1ra) prevents heart failure and improves long-term survival in a real-world population as compared with SGLT2i or GLP1ra monotherapy, according to a study.

Infants born to mothers with prepregnancy obesity are at risk of sudden unexpected infant death (SUID), with the risk increase commensurate with maternal BMI, according to a large US nationwide cohort study.

The antilipidemic drug fenofibrate averts or delays diabetic retinopathy (DR) in diabetes patients with early retinal changes in the LENS trial, potentially paving the way for the least invasive route of drug delivery in this population.